Back to discover
Drug

Medroxyprogesterone Acetate

In clinical development
ClassProgesterone receptor agonistEmerging researchLate-stage development
Also known as 6-alpha-Methyl-17-alpha-acetoxyprogesterone, Amen, Curretab, Cycrin+12 more

6-alpha-Methyl-17-alpha-acetoxyprogesterone, Amen, Curretab, Cycrin, Depo-Provera, Depo-Provera Contraceptive, Lunelle, MPA, Methylacetoxyprogesterone, Metigestrona, Prempro, Provera, depo-subQ provera, 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate, Medroxyacetate progesterone, Medroxyprogesterone 17-acetate.

RxNorm1000112ChEMBLCHEMBL717ATCL02AB02ATCG03AC06ATCG03DA02UNIIC2QI4IOI2G
2
Research papers
6
Active clinical trials
Progesterone receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months

Clinical trial2026-06-23Results expected Q4 2027 · ClinicalTrials.gov

Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer

Clinical trial2026-06-04Results expected Q1 2027 · ClinicalTrials.gov

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial

Clinical trial2026-05-15Results expected Q1 2030 · ClinicalTrials.gov

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

Clinical trial2026-04-10Completed · ClinicalTrials.gov

Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）

Clinical trial2026-03-13Results expected Q4 2027 · ClinicalTrials.gov

A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)

Clinical trial2026-02-02Results expected Q4 2027 · ClinicalTrials.gov

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Clinical trial2025-06-15Primary completion · ClinicalTrials.gov

Comparison of Cetrorelix, Medroxyprogesterone Acetate and Dydrogesterone for Preventing Premature Ovulation in Ovarian Stimulation Cycles

Clinical trial2024-09-30Completed · ClinicalTrials.gov

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma

Clinical trial2024-09-19Results posted · ClinicalTrials.gov

The Therapeutic Effect of Medroxyprogesterone Acetate vs. LNG-IUS in Early-stage Endometrioid Carcinoma

Clinical trial2024-07-01Primary completion · ClinicalTrials.gov

Menopausal hormone therapy and change in physical activity in the Women's Health Initiative hormone therapy clinical trials.

Research2023-08-01Menopause (New York, N.Y.)

Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.

Research2012-09-07Contraception

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Medroxyprogesterone Acetate
Aliases & brands
6-alpha-Methyl-17-alpha-acetoxyprogesteroneAmenCurretabCycrinDepo-ProveraDepo-Provera ContraceptiveLunelleMPAMethylacetoxyprogesteroneMetigestronaPremproProveradepo-subQ provera6-alpha-Methyl-17-alpha-hydroxyprogesterone acetateMedroxyacetate progesteroneMedroxyprogesterone 17-acetate
RxNorm CUI
1000112
ChEMBL ID
CHEMBL717
ATC codes
L02AB02G03AC06G03DA02
UNII
C2QI4IOI2G
Primary mechanism
Progesterone receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Progesterone receptor
PGR · P06401
AGONISTProgesterone receptor agonist

Clinical trials

36 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
36
registered trials across all phases
LATEST COMPLETION 2026
6
Active studies
6
Recruiting
28
Late-stage (III+)
24
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 36
Early Phase 11Phase 12Phase 25Phase 2 / 35Phase 310Phase 48Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Not yet recruitingPH IVGinefivn=1442025

The Rate of Embryo Euploidy in Women Treated With Progestin-primed Ovarian Stimulation Versus Conventional Ovarian Stimulation: a Randomized Controlled Trial

Unknown statusPH IVCasa di Cura Privata Villa Mafaldan=3962022

Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA

CompletedPH IVLorenzo Gallonn=282020

Is Endometrial Withdrawal Bleeding Necessary Prior to Ovulation Induction With Clomiphene Citrate? A Randomized Controlled Trial and Feasibility Study

CompletedPH IVRadboud University Medical Centern=422018

The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study

CompletedPH IVSamuel Lunenfeld Research Institute, Mount Sinai Hospitaln=502015

Recent completions

Trials that read out recently, adding to the completed evidence base.

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

CompletedPH IIITB-Med LLCn=762026

Comparison of Cetrorelix, Medroxyprogesterone Acetate and Dydrogesterone for Preventing Premature Ovulation in Ovarian Stimulation Cycles

CompletedN/ABezmialem Vakif Universityn=2972024

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma

CompletedPH IIGOG Foundationn=742024

Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

CompletedPH IIIXiaojun Chenn=4712022

A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus

CompletedPH INational Cancer Institute (NCI)n=502021

Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

CompletedPH IIIAssiut Universityn=2402021

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20122023
Major research themes3
Estrogens1Estrogens, Conjugated (USP)1Intrauterine Devices, Medicated1
Journals, researchers & institutions
Top journals
  • Contraception1
  • Menopause (New York, N.Y.)1
Leading researchers
  • Bissonnette F1
  • Chlebowski RT1
  • Coday M1
  • DeSanctis Y1
  • Jensen J1
  • Johnson KC1
  • Jung SY1
  • Kaunitz AM1
Leading institutions
free-text, unnormalised
  • Albert Einstein College of Medicine1
  • Brigham and Women's Hospital1
  • Brigham's and Women's Hospital1
  • College of Medicine1
  • Dornsife School of Public Health1
  • Herbert Wertheim School of Public Health and Human Longevity Science1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Estrogens

Frequently co-studied with Medroxyprogesterone Acetate in the research literature.

1 shared paper
Estrogens, Conjugated (USP)

Frequently co-studied with Medroxyprogesterone Acetate in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials